Publication

Genetic evaluation and testing for hereditary forms of cancer in the era of next-generation sequencing

Downloadable Content

Persistent URL
Last modified
  • 02/20/2025
Type of Material
Authors
    Christine Stanislaw, Emory UniversityYuan Xue, Fulgent DiagnosticsWilliam Wilcox, Emory University
Language
  • English
Date
  • 2016-03-01
Publisher
  • Chinese Anti-cancer Association (CACA)
Publication Version
Copyright Statement
  • © 2016 by Cancer Biology & Medicine.
License
Final Published Version (URL)
Title of Journal or Parent Work
ISSN
  • 2095-3941
Volume
  • 13
Issue
  • 1
Start Page
  • 55
End Page
  • 67
Abstract
  • The introduction of next-generation sequencing (NGS) technology in testing for hereditary cancer susceptibility allows testing of multiple cancer susceptibility genes simultaneously. While there are many potential benefits to utilizing this technology in the hereditary cancer clinic, including efficiency of time and cost, there are also important limitations that must be considered. The best panel for the given clinical situation should be selected to minimize the number of variants of unknown significance. The inclusion in panels of low penetrance or newly identified genes without specific actionability can be problematic for interpretation. Genetic counselors are an essential part of the hereditary cancer risk assessment team, helping the medical team select the most appropriate test and interpret the often complex results. Genetic counselors obtain an extended family history, counsel patients on the available tests and the potential implications of results for themselves and their family members (pre-test counseling), explain to patients the implications of the test results (post-test counseling), and assist in testing family members at risk.
Author Notes
Keywords
Research Categories
  • Health Sciences, Oncology
  • Biology, Genetics

Tools

Relations

In Collection:

Items